Blood advances · 2018
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aljama Mohammed A, Sidiqi M Hasib, Lakshman Arjun, Dispenzieri Angela, Jevremovic Dragan, Gertz Morie A, Lacy Martha Q, Buadi Francis K, Dingli David, Muchtar Eli, Fonder Amie L, Hayman Suzanne R, Hobbs Miriam A, Gonsalves Wilson I, Warsame Rahma, Kourelis Taxiarchis V, Hwa Yi Lisa, Kapoor Prashant, Leung Nelson, Go Ronald S, Kyle Robert A, Rajkumar S Vincent, Kumar Shaji K
Аннотация
The plasma cell proliferative index (PCPI), determined by a slide technique or by flow cytometry, detects cells in the S phase of the cell cycle and is a useful prognostic tool in patients with plasma cell disorders such as multiple myeloma and amyloidosis. We conducted a retrospective review analyzing the prognostic effect of PCPI in 306 patients with smoldering multiple myeloma (SMM). Seventy-nine (26%) patients had an elevated PCPI (>0.5). An elevated PCPI predicted an inferior time to progression (median, 3.0 vs 7.1 years for those with a low PCPI; P = .0004). Within 24 months, the progression rate was significantly higher for patients with an elevated PCPI (49% vs. 20%; P < .0001). PCPI is a valuable tool in risk stratifying patients with SMM and identifies patients with earlier progression who may benefit from closer follow-up and consideration of early intervention trials.